Kedrion, Kamada partner to combat COVID-19

By The Science Advisory Board staff writers

April 29, 2020 -- Biopharmaceutical firms Kedrion Biopharma and Kamada are collaborating on the creation and clinical distribution of a plasma-derived anti-SARS-CoV-2 treatment product.

The two companies hope to obtain approval for the clinical treatment of patients severely ill with COVID-19. The initial focus of the collaboration will be in Italy, Israel, and the U.S., with plans to subsequently expand development and distribution efforts to additional markets.

Kedrion will provide plasma collected at its KedPlasma centers from donors in both Europe and the U.S. who have recovered from the novel coronavirus. KedPlasma USA has received clearance from the U.S. Food and Drug Administration (FDA) and has begun to collect COVID-19 convalescent plasma from three centers, two of which are the greater Atlanta, GA area, and one facility in Mobile, AL. The company plans to expand its collection efforts to Europe, Australia, and South Korea.

Concurrently, Kamada will handle product development, manufacturing, clinical development, and regulatory submissions. The company also will distribute the SARS-CoV-2 products, while marketing rights in China will be shared by both companies.

Kedrion is in contact with health authorities in Italy, the home of its headquarters, while Kamada is in touch with the Israeli authorities where it is based. The companies also plan to connect with the FDA and the European Medicine Agency to seek an accelerated regulatory path to bring the anti-SARS-CoV-2 products to market.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here